OR WAIT 15 SECS
© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
July 30, 2020
Advocates say a number of regulatory changes could help bring more of these products on to the market.
July 24, 2020
Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.
July 09, 2020
Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.
July 08, 2020
Along with the other Humira biosimilars, Hulio will not be on the market till 2023.
July 06, 2020
Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs
July 02, 2020
Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars.
June 04, 2020
Proving therapeutic equivalence is a major hurdle.
Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.
May 18, 2020
The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.
Just as we’ve seen the entire healthcare landscape change in 2020 because of COVID-19, the world of biosimilars is ever-changing.